The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation.

Globally, lung cancer remains the most common cause of cancer mortality, with non-small-cell lung cancer (NSCLC) being the most common subtype of lung cancer diagnosed. This review paper provides a comprehensive landscape of clinical prediction models (CPMs) in NSCLC, including in early-stage and metastatic disease, and the recent acceleration of artificial intelligence integration. Prediction models are developed using multimodal patient data to allow oncologists to make evidence-based decisions regarding patient treatment options.

Online tool for cross-sectional and longitudinal comparison of socio-economic status indices based on postcodes in Australia.

Background: Socio-economic status (SES) is strongly associated with health outcomes, yet it remains relatively difficult to measure, particularly for longitudinal comparisons.

Aim: We have developed an interactive online tool (available at bit.ly/SEIFA-POA) that facilitates SES assessment based on postcodes (POA).

Impact of a hybrid, short-term prehabilitation on patient-reported outcomes in patients undergoing lung resection for non-small cell lung cancer.

Objectives: We examined the impact of short-term, multimodal prehabilitation on perioperative functional and patient-reported outcomes (PROs) in patients undergoing surgical resection for non-small cell lung cancer (NSCLC).

Methods: This is a retrospective study with paired comparisons on consecutive patients worked up for surgical resection for suspected NSCLC referred for prehabilitation including exercise, nutritional, and PROs assessment in a single centre from October 2022 to August 2023. Patients participated in a hybrid programme, with twice-weekly, one-to-one sessions combing high-intensity interval-style and strength training with accompanying app-based exercise and lifestyle support.

Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudy.

Aims: Haptoglobin (HP) phenotype has been reported to modulate fenofibrate benefit on coronary artery disease in type 2 diabetes. It is unknown whether HP phenotype and levels modulate fenofibrate benefit on sight-threatening diabetic retinopathy (STDR).

Methods: In plasma from 8,047 Australasian adults with type 2 diabetes in the FIELD trial, HP phenotype was determined, and HP levels were measured at baseline and after six-week fenofibrate run-in.